A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
03/02/2022at 07:55

Novo CEO: Obesity goal within touching distance well before 2025 deadline

Novo Nordisk may be able to realize its ambition to double the size of its obesity business compared to 2019 levels three years early. A new target may be revealed soon.
Photo: Stine Bidstrup/ERH
by marketwire, translated by catherine brett

Danish pharmaceutical giant Novo Nordisk is well on the way to achieving its 2025 goal for sales of weight loss drugs three years early. There is therefore a good chance that a new target will be revealed at the company’s upcoming capital markets day, on March 3.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Novo Nordisk / PR

    Obesity business grows at Novo Nordisk despite Wegovy woes

    For subscribers

  • Photo: Kevin Grønnemann

    Novo Nordisk plans to submit weekly growth hormone for approval in H1

    For subscribers

  • Karsten Munk Knudsen, CFO at Novo Nordisk | Photo: Novo Nordisk / PR

    Novo Nordisk invests billions of dollars in post-semaglutide future

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Further reading

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Pharma & biotech

Novo Nordisk to test anti-obesity molecule in triple the highest approved dose

Two late-stage studies of semaglutide, the substance in Novo Nordisk’s new and popular obesity treatment, are set to commence imminently.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of International Sales

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Experienced Patent Counsel

  • Principal Laboratory Technologist

  • Commercial Director

See all jobs

Jobs

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of International Sales

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Experienced Patent Counsel

  • Principal Laboratory Technologist

  • Commercial Director

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge